CJC-1295 & Ipamorelin Injection Frequency Explained

CJC-1295/Ipamorelin injection frequency is not a number printed on an approved drug label, because neither peptide carries one. This reference explains what actually determines frequency in research protocols, and, more usefully, how frequency interacts with the reconstitution math that decides how long a vial lasts. It is written for research and educational purposes only and is not medical advice.

No approved label sets a fixed frequency

Some research peptides carry an FDA-approved formulation with a labeled schedule — tesamorelin, for instance, has an approved once-daily label for its narrow indication, indexed on DailyMed (NIH/NLM). Neither CJC-1295 nor Ipamorelin has an equivalent approved injectable drug label. Without that regulatory anchor, there is no single "correct" CJC-1295/Ipamorelin injection frequency — only frequencies that show up across different research write-ups, which vary from source to source.

That absence of a fixed standard matches how this blend is treated elsewhere on this site: there's no official water volume for reconstitution either, only reference concentrations chosen because they read cleanly on a syringe (see the CJC-1295 & Ipamorelin dosage chart). Frequency works the same way — a protocol detail set by whoever designed the specific research use, not a figure handed down from an approved label.

What frequency actually controls

Frequency answers one question: how many times per period does a draw come out of the vial. It says nothing about a separate question: what concentration is in the vial. That second question is fixed the moment bacteriostatic water is added:

Concentration = vial mass (mg) ÷ water added (mL)

A vial reconstituted to a given concentration stays at that concentration through every draw, whether the schedule calls for one draw a day or one draw a week. Frequency and concentration are independent variables that combine into a third, more practical number: how many days a single vial actually covers.

Blend vials and separate vials read frequency differently

CJC-1295 and Ipamorelin reach researchers in one of two formats, and each has its own frequency bookkeeping:

• Pre-blended vial — one vial holds both peptides, commonly at a 1:1 ratio by weight (5 mg CJC-1295 / 5 mg Ipamorelin, labeled "5 mg/5 mg" for 10 mg total). One frequency, one draw, pulls both peptides at once.
• Separate vials — each peptide has its own vial, its own concentration, and its own doses-per-vial count. The two schedules only need to line up if the intent is to draw both peptides together.

Check the label before applying any frequency estimate to it. A "5 mg/5 mg" vial is 10 mg total, not 5 mg — using the wrong figure throws off the doses-per-vial count before frequency even enters the calculation.

Worked example: vial life at two frequencies

Take a 10 mg blend vial (5 mg CJC-1295 / 5 mg Ipamorelin) reconstituted with 2 mL of bacteriostatic water, at a 0.5 mg blend dose per draw — the same reference setup used in the CJC-1295 & Ipamorelin dosage chart.

Step 1 — concentration. 10 mg ÷ 2 mL = 5 mg/mL.

Step 2 — volume per dose. 0.5 mg ÷ 5 mg/mL = 0.1 mL.

Step 3 — syringe units. On a U-100 insulin syringe, 1 mL equals 100 units, so 0.1 mL × 100 = 10 units per draw.

Step 4 — doses per vial. 10 mg ÷ 0.5 mg = 20 doses. This depends only on vial mass and dose size — the water volume in Step 1 doesn't change it.

Step 5 — vial life by frequency. At once daily, 20 doses run 20 days, about 2.9 weeks. At every other day, the same 20 doses stretch to 20 × 2 = 40 days, about 5.7 weeks. Neither frequency is a recommendation here — they're two illustrative points showing how the same vial and dose produce different vial-life figures depending on how often it's drawn.

A larger 20 mg blend vial (10 mg CJC-1295 / 10 mg Ipamorelin) reconstituted with 4 mL of water is also 20 ÷ 4 = 5 mg/mL, matching the same 10-unit draw for a 0.5 mg dose. It holds 20 mg ÷ 0.5 mg = 40 doses: 40 days at once daily (about 5.7 weeks), or 80 days at every other day (about 11.4 weeks).

Blend vial	Water added	Concentration	0.5 mg dose (units)	Doses per vial	Vial life — once daily	Vial life — every other day
10 mg	2 mL	5 mg/mL	10 units	20	20 days (~2.9 weeks)	40 days (~5.7 weeks)
20 mg	4 mL	5 mg/mL	10 units	40	40 days (~5.7 weeks)	80 days (~11.4 weeks)

Because the vial is a 1:1 blend, each 0.5 mg draw splits into 0.25 mg CJC-1295 and 0.25 mg Ipamorelin. Multiply that split by the 20 doses in the 10 mg reference vial and the totals land back on the label exactly: 20 × 0.25 mg = 5 mg of each peptide. The same check works for the 20 mg vial — 40 × 0.25 mg = 10 mg of each. If a chosen frequency and dose don't divide evenly back into the labeled per-peptide amounts, the input numbers are worth rechecking before drawing anything.

Frequency and dose size are separate decisions

It's easy to assume a higher CJC-1295/Ipamorelin injection frequency automatically means a smaller per-draw dose, since that pattern shows up in some protocols. The arithmetic doesn't require it. A protocol can hold the dose steady and simply draw from the vial more often, which empties it faster, or it can lower the dose to stretch the same vial across more frequent draws. Frequency, dose size, and vial life are three separate numbers connected by the doses-per-vial formula above — changing one doesn't automatically change another unless the protocol is designed that way.

Why research protocols on frequency disagree

Because there's no approved label to converge around, published and self-reported CJC-1295/Ipamorelin protocols describe a range of schedules rather than one standard. Some describe once-daily draws; others space them out further. This guide does not recommend a frequency or take a position on which protocol is better — that's a research-design question outside the scope of a reconstitution reference, and outside what a calculator can tell you. What the math above shows is how any given frequency plays out against a specific vial size, water volume, and dose once one has been chosen.

Keeping frequency and concentration from drifting apart

A frequency-based vial-life estimate is only accurate if the concentration behind it hasn't changed. Track the date a vial was reconstituted, not just when it was opened — see how to store reconstituted peptides for the general reasoning. If a vial that should supply 20 doses at 5 mg/mL runs out sooner than the frequency and dose size predict, the concentration used in the original calculation is the more likely source of the mismatch, not the compound itself.

Common mistakes

• Looking for an official CJC-1295/Ipamorelin injection frequency. No approved label sets one — treat any specific number as a protocol detail, not a standard.
• Assuming frequency changes concentration. It doesn't. Concentration is fixed at reconstitution; frequency only affects how fast the vial's total mg gets drawn down.
• Reading a blend label as per-peptide when it's total mass, or the reverse. A "5 mg/5 mg" vial is 10 mg total, not 5 mg.
• Reusing a vial-life estimate after changing the water volume or dose. The 20-day and 40-day figures above only hold at 5 mg/mL and a 0.5 mg dose. Change either input and the vial-life number changes with it.
• Confusing dose size with frequency. They're independent choices, not two names for the same variable.

Use the calculator

Enter your CJC-1295/Ipamorelin vial size, bacteriostatic water volume, and target dose into the peptide dosage calculator to get the exact concentration, draw volume, and syringe units, then apply your intended frequency to the doses-per-vial figure to estimate vial life. For the full dose-to-units breakdown across common vial sizes, see the CJC-1295 & Ipamorelin dosage chart; for how the water ratio itself is chosen, see CJC-1295 & Ipamorelin bac water ratio.